Bank of America Global Research just trimmed its price target on Eli Lilly, bringing it down slightly to $1,265 from the previous $1,268. It's a modest downward revision—we're talking just three bucks—but these tweaks from major investment banks don't happen in a vacuum. They typically reflect updated assumptions about the company's earnings trajectory, competitive positioning, or broader market conditions. For investors tracking the pharma giant's valuation, this kind of recalibration is worth monitoring, especially when it comes from a tier-one research outfit. The question now: is this a sign of broader caution on the sector, or simply a fine-tuning of Eli Lilly's specific story? Market watchers will be keeping tabs on what other analysts say in the coming weeks.